Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Arcus Biosciences, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 183 | 2 | 200 | +19 |
| Shares | 52.5M | 712 | 53.8M | +1.31M (+2.5%) |
| Value | $1.37B | $19.0K | $1.11B | −$260.6M (−19.0%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (41)
Institutions that held Arcus Biosciences, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (22)
Institutions that held Arcus Biosciences, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Perceptive Advisors LLC | 666,477 | $17.4M |
| Finepoint Capital LP | 646,586 | $16.9M |
| OrbiMed Advisors LLC | 303,000 | $7.93M |
| Endurant Capital Management LP | 97,327 | $2.55M |
| Two Sigma Investments, LP | 49,891 | $1.30M |
| UBS Oconnor LLC | 38,725 | $1.01M |
| AlphaCrest Capital Management LLC | 35,523 | $929.0K |
| Graham Capital Management, L.P. | 29,867 | $781.0K |
| Occudo Quantitative Strategies LP | 28,451 | $744.0K |
| Ensign Peak Advisors, Inc | 9,880 | $258.0K |
| Personal Capital Advisors Corp | 9,395 | $246.0K |
| Voloridge Investment Management, LLC | 8,771 | $229.0K |
| NinePointTwo Capital | 8,732 | $228.0K |
| Diversified Trust Co | 8,645 | $226.0K |
| Handelsbanken Fonder AB | 8,500 | $222.0K |
| Cornercap Investment Counsel Inc | 8,138 | $213.0K |
| Neuberger Berman Group LLC | 7,837 | $212.0K |
| MML Investors Services, LLC | 7,741 | $203.0K |
| Group One Trading, L.P. | 5,833 | $153.0K |
| Islay Capital Management, LLC | 1,776 | $46.0K |
| Ronald Blue Trust, Inc. | 40 | $1.00K |
| Meeder Asset Management Inc | 12 | $0 |
Not filed for Q4 2022 yet (2)
Institutions that held Arcus Biosciences, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Wipfli Financial Advisors LLC, | 424 | $11.0K |
| New Century Advisors, LLC | 288 | $8.00K |